Loading
A phase 3 trial of Ivonescimab, Pemetrexed, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, active and no longer recruiting.
Phase III Study of AK112 for NSCLC Patients is a phase 3 interventional study registered as NCT06396065 by Summit Therapeutics, with 420 participants enrolled, started 2023-05-04 and due to reach its primary completion in 2025-04-12. Interventions recorded: AK112 Injection, Placebo Injection. Conditions listed: Non-Squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Summit Therapeutics, Ivonescimab, Pemetrexed, Platinum agents.
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Summit Therapeutics, Ivonescimab, Pemetrexed, Platinum agents.
Shares Pemetrexed, Platinum agents, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Platinum agents, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/